目的:观察亚砷酸(三氧化二砷,As2O3)联合GDP方案(吉西他滨,顺铂,地塞米松)治疗难治性或复发性非霍奇金淋巴瘤(non-hodgkin's lymphoma,NHL)的有效率.方法:23例难治性或复发性非霍奇金淋巴瘤(NHL),给予吉西他滨1000mg/m2,第1和第8天,顺铂25mg/m2 第1-3天,地塞米松 20mg/m2,第1-5天,As2O310mg/d,第1-14天.21天为1个周期.结果:完全缓解9例,部分缓解6例,总有效率65.22%.肿瘤中位进展时间6个月,1年生存率39.13%.不良反应主要为血液学毒性.结论:亚砷酸联合GDP方案是治疗难治性或复发性非霍奇金淋巴瘤较为安全有效的化疗方案.%Objective:To evaluate the efficacy and safety of chemotherapy regimen with arsenic trioxide ( As2 O3 )combined with GDP ( gemcitabine, cisplatin and dexamethasone ) for patients with aggressive relapsed or refractory NHL. Methods: All 23 patients with relapsed or refractory NHL were observed,23 patients were treated by gemcitabine 1000 mg/m2 on d1 ,8, cisplatin 25 mg/m2 on d1-3 and dexamethasone 25 mg/m2 on d1-5, Arsenic oxide 10mg/d on d1-14。 21 days for a cycle. Results: Of experimental group all response rate was 65.22％ ,including 9 complete response and 6 partial response. Median time to progression was 6 months, and 1 year survival rate was 39.13％.The major adverse reaction was toxicity of bone marrow. Conclusion: Arsenic trioxide combined with GDP regimen is effective and safe for patients with aggressive relapsed or refractory non - Hodgkin's lymphoma.
展开▼
